OverviewChartTechnicalNewsTraderScreen

Celldex Therapeutics Inc/  US15117B2025  /

NASDAQ
2024-04-18  10:00:00 PM Chg. -1.1000 Volume Bid11:34:50 PM Ask11:34:50 PM High Low
38.5300USD -2.78% 576,622
Turnover: 16.31 mill.		 35.0000Bid Size: 1,000 38.4700Ask Size: 100 39.9400 38.2900
GlobeNewswire 04-17 Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chroni...
GlobeNewswire 03-08 Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
GlobeNewswire 03-05 Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
GlobeNewswire 03-05 Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Under...
GlobeNewswire 03-01 Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
GlobeNewswire 02-28 Celldex Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire 02-26 Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
GlobeNewswire 02-24 Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic S...
GlobeNewswire 02-06 Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GlobeNewswire 02-05 Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urti...
GlobeNewswire 2023-12-27 Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
GlobeNewswire 2023-12-07 Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
GlobeNewswire 2023-11-27 Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
GlobeNewswire 2023-11-08 Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire 2023-11-07 Celldex Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire 2023-11-06 Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic ...
GlobeNewswire 2023-11-05 Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Mean...
GlobeNewswire 2023-11-02 Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-09-26 Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at ...
GlobeNewswire 2023-09-26 Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Inn...
GlobeNewswire 2023-09-25 Celldex Therapeutics to Present at Cantor Global Healthcare Conference
GlobeNewswire 2022-02-28 Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
GlobeNewswire 2022-02-22 Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Confere...
GlobeNewswire 2022-02-10 Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
GlobeNewswire 2021-12-17 Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer